Overview

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

Status:
Recruiting

Trial end date:
2038-11-01

Target enrollment:

Participant gender:

Summary

The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG/PTCy) to 45% (Pick-a-winner phase 2 randomized study).

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital of Liege
University of Liege

Collaborators:

Belgian Hematological Society
Belgian Hematological Society Transplant Committee

Treatments:

Antilymphocyte Serum
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Melphalan
Thymoglobulin
Vidarabine